A research letter published yesterday in the New England Journal of Medicine looks at delayed injection-site skin reactions to the Moderna COVID-19 vaccine four to 11 days after 12 people received the first dose. All 12 received a second dose, since delayed injection-site or hypersensitivity reactions are not contraindications for subsequent vaccination. Three of them experienced a similar skin reaction and three a lesser reaction one to three days after the second dose, the authors said. Most received treatment for their symptoms, which resolved two to 11 days after onset. Delayed injection-site reactions occurred in 0.8% of the 30,420 participants in a phase 3 clinical trial of the vaccine, the study notes.

“We hope this letter encourages additional reporting and communication regarding the epidemiologic characteristics, causes, and implications of these delayed cutaneous reactions, since this information might allay the concerns of patients, encourage completion of vaccination, and minimize the unnecessary use of antibiotic agents,” the authors said.

Related News Articles

Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…